Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant depression. Methods: This Phase 3, double-blind, multicenter study enrolled adults with moderate-to-severe depression and nonresponse to ≥2 antidepressants in the current depression episode. Eligible patients (N = 346) were randomized (1:1:1) to twice-weekly nasal spray treatment (esketamine [56 or 84 mg] or placebo) plus a newly initiated, open-label, oral antidepressant taken daily for 4 weeks. The primary efficacy endpoint was change from baseline to day 28 in the Montgomery-Asberg Depression Rating Scale total score, performed by blinded, remote raters. Based on the predefined statistical testing sequence, esketamine 84 mg/antidepressant had to be significant for esketamine 56 mg/antidepressant to be formally tested. Results: Statistical significance was not achieved with esketamine 84 mg/antidepressant compared with antidepressant/placebo (least squares [LS] means difference [95% CI]: –3.2 [–6.88, 0.45]; 2-sided P value = .088). Although esketamine 56 mg/antidepressant could not be formally tested, the LS means difference was –4.1 [–7.67, –0.49] (nominal 2-sided P value = .027). The most common (>20%) adverse events reported for esketamine/antidepressant were nausea, dissociation, dizziness, vertigo, and headache. Conclusions: Statistical significance was not achieved for the primary endpoint; nevertheless, the treatment effect (Montgomery-Asberg Depression Rating Scale) for both esketamine/antidepressant groups exceeded what has been considered clinically meaningful for approved antidepressants vs placebo. Safety was similar between esketamine/antidepressant groups and no new dose-related safety concerns were identified. This study provides supportive evidence for the safety and efficacy of esketamine nasal spray as a new, rapid-acting antidepressant for patients with treatment-resistant depression. Trial Registration: ClinicalTrials.gov identifier: NCT02417064
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Least squares mean change (±SE) in Montgomery-Asberg Depression Rating Scale (MADRS) total score over time in double-blind phase (observed cases mixed model for repeated measures [MMRM]). LS, least squares; SE, standard error. LS mean and SE were based on MMRM with change from baseline as the response variable and the fixed effect model terms for treatment (esketamine 56 mg/antidepressant, esketamine 84 mg/antidepressant, antidepressant/placebo), day, region, class of oral antidepressant, and treatment-by-day, and baseline value as a covariate. Results are not adjusted for multiple comparisons or sample size reestimation. Negative change in score indicates improvement.](https://figures.cochat.ai/paper-figures/2c4f045dfb03494db68f2585854e303a/efficacy-and-safety-of-fixed-dose-esketamine-nasal-spray-combined-with-a-new-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Fedgchin’s group conducted an analogous study, which did not support adjunctive esketamine’s AD efficacy for TRD [111].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [111]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials found that esketamine, in combination with an oral antidepressant, rapidly reduced suicidal thoughts compared to placebo in adults with TRD who were at imminent risk for suicide [65,88,89].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In one of those (NCT02417064 [9]), statistical significance should not have been tested for the 56 mg treatment group due to the hierarchical analysis and the absence of a significant difference in the 84 mg group tested first.”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, when reviewing the major esketamine trials, significantly increased rates of somnolence versus placebo have been reported, especially in relapse-prevention studies,74,152 but this has not been seen consistently.153”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [152]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because this was statistically tested when it should not have been, it introduced some spin into the published report [9], despite the numerical results being deemed reproducible.”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [9]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Diagnostic and Statistical Manual of Mental Disorders(DSM)
(2008) · Encyclopedia of Counseling · doi:10.4135/9781412963978.n182 · Cited by 10,830
Spitzer, R. L. (1999) · JAMA · doi:10.1001/jama.282.18.1737 · Cited by 9,802
(1976) · Medical Entomology and Zoology · Cited by 8,899
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“In patients who respond to biogenic amine antidepressants, the time to onset of effect is typically 3 to 7 weeks, during which time patients remain symptomatic and at risk of self-harm (Rush et al., 2006).”
BackgroundSelf-citationDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 5×
“About one-third of patients with MDD fail to achieve remission despite treatment with multiple biogenic amine (e.g., serotonin, norepinephrine) antidepressants and hence have treatment-resistant depression (TRD) (Fava, 2003).”
BackgroundMethodInfluentialSelf-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Self-citationPosner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025
Cited by
Items 301–400 of 679
Thornton, N. L. R., Black, W., Bognar, A., Dagge, D., Gitau, T., Hua, B., Joks, G., King, J., Lord, A., Scott, E. M., et al. (2023) · Asia-Pacific Psychiatry · doi:10.1111/appy.12550 · Cited by 5
Samalin, L., Mékaoui, L., de Maricourt, P., Sauvaget, A., Codet, M. A., Gaudre-Wattinne, E., Wicart, C., & Rothärmel, M. (2024) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2024.2398788 · Cited by 5
Oliveira-Maia, A. J., Rive, B., Godinov, Y., & Mulhern-Haughey, S. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1459633 · Cited by 5
Kavakbasi, E., Rosemann, K., Yilmaz, M., Berndt, H., & Baune, B. T. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02041-9 · Cited by 4
Fountoulakis, K. Ν., Tatsiopoulou, P., Saitis, A., Fountoulakis, N. K., & Schatzberg, A. F. (2025) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-025-02897-1 · Cited by 4
Masdrakis, V. G., Tebbs, Z., Natsis, V., & Baldwin, D. S. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251389583 · Cited by 4
Li, X., Mao, H., Luo, J., Jiang, W., Li, P., Zhou, L., Tian, L., Liu, Z., & Qiu, Y. (2025) · Actas Españolas de Psiquiatría · doi:10.62641/aep.v53i6.2044 · Cited by 4
An Update on Somatic Treatments for Suicide Risk
Rizk, M., & Mann, J. J. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260287 · Cited by 4
Beyond Anesthesia: Ketamine’s Expanding Role in Chronic Pain and Psychiatric Disorders
Zaki, C. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin26766 · Cited by 4
Gonadotropin-Dependent Precocious Puberty: Single-Center Experience From Western India
Phadte, A., Sarathi, V., Budyal, S. R., Lila, A. R., Memon, S. S., Karlekar, M. P., Patil, V. A., Shah, N. S., & Bandgar, T. (2023) · Indian Pediatrics · doi:10.1007/s13312-023-2909-y · Cited by 4
The “new wave” of antidepressants: are these agents paradigm-shifters in treating major depression?
Petrescu, B. M., Marinescu, I. P., Marinescu, D., Vasiliu, O., Mangalagiu, A. G., & Cândea, C. A. (2023) · Psihiatru ro · doi:10.26416/psih.75.4.2023.8926 · Cited by 4
Les propriétés antidépressives de la kétamine: Une revue
Desfossés, C. Y., & Blier, P. (2021) · médecine/sciences · doi:10.1051/medsci/2020256 · Cited by 4
Self-citationGil, T., & Bonetti, T. C. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100809 · Cited by 3
Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study
Veraart, J. K. E., Vos, C. F., Punt, N. C., Visser, D., Wessels, A. M. A., Smith-Apeldoorn, S. Y., Kamphuis, J., Schoevers, R. A., & Touw, D. J. (2025) · Pharmaceuticals · doi:10.3390/ph18050627 · Cited by 3
Ayad, N., Aziz, K. A., Makhoul, S., Abbas, B., & Javaid, S. F. (2026) · BJPsych Open · doi:10.1192/bjo.2025.10950 · Cited by 3
Pharmacological treatment of adolescent depression: Current advances and future perspectives
Li, Y., Wang, F., Chen, G., & Zhai, S. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100278 · Cited by 3
Ketamine pharmacotherapy for major depressive disorder: A narrative review
Miller, C. H., Hickman, A., Baten, C., Ali, Z., Kahlon, S. K., Klassen, A. M., Zamora, G., Shepherd, J. H., Venegas, G., Miller, J. A., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111651 · Cited by 3
Ketamine as a Bridge Therapy: Reducing Acute Suicidality in Hospital Settings
Lie, P. E., Lie, T., Nguyen, M., & Lie, D. Y. C. (2026) · Healthcare · doi:10.3390/healthcare14050634 · Cited by 3
Chronic Pain and Major Depression: Shared Psychological and Neurobiological Mechanism
Lee, S.-H., & Kim, Y. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-981-95-6872-7_9 · Cited by 3
Hu, H.-L., Huang, Q.-Z., & Xie, P.-X. (2026) · Medicine · doi:10.1097/md.0000000000048570 · Cited by 3
Schüle, C., Sobieraj, A., & Rogg, H. V. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2742-4611 · Cited by 3
Chen, B. K., Whye, A., Matthews, L. C., Moniz, T., Mendez‐David, I., Gardier, A. M., David, D. J. P., Johns, S., Weisblum, E., & Denny, C. A. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02107-1 · Cited by 3
Ding, J., Yang, Y., Cao, D., Wang, T., & Yu, Q. (2025) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.16311 · Cited by 3
Expanding Ketamine Application for Treatment of Acute Suicidality in Long-Duration Spaceflight
Kutz, C. J., Mistry, A. M., & Dukes, C. H. (2025) · Aerospace Medicine and Human Performance · doi:10.3357/amhp.6619.2025 · Cited by 3
Chatterton, M. L., Perez, J. K., Thai, T. T. H., Faller, J., Loo, C. K. A., Glozier, N., Barton, D., Baune, B. T., Mills, N. T., Fitzgerald, P. B., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119502 · Cited by 3
Chen, B. K., Hunsberger, H. C., Whye, A., Matthews, L. C., Yook, A., Willner, M. J., Logan, R. W., Johns, S., Weisblum, E., & Denny, C. A. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01804-9 · Cited by 3
Santucci, M. C., Katz, R. B., Pittman, B. P., Nikayin, S., & Wilkinson, S. T. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06896-7 · Cited by 3
Alborghetti, M., Lionetto, L., Lombardozzi, G., Montaguti, L., Trovini, G., Donato, D., Costanzi, G., Bernardini, D. D., Catapano, F., Surano, M., et al. (2025) · Current Neuropharmacology · doi:10.2174/011570159x356952241216172603 · Cited by 3
González-Pinto, A. M. (2020) · Psiquiatría Biológica · doi:10.1016/j.psiq.2020.01.001 · Cited by 3
Esketamine nasal spray for treatment‐resistant depression
Chaplin, S. (2020) · Prescriber · doi:10.1002/psb.1845 · Cited by 3
Zheng, W., Sim, K., Ning, Y., & Xiang, Y. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.154 · Cited by 3
Consistency of the Antidepressant Effect of Intranasal Esketamine in Phase 3 Clinical Trials
Preskorn, S. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000531 · Cited by 3
Self-citationNovel experimental and early investigational drugs for the treatment of bipolar disorder
Carta, M. G., Kalcev, G., Fornaro, M., & Nardi, A. E. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.2000965 · Cited by 3
Suizidpräventive Effekte von Ketamin und Esketamin
Plöderl, M., Hengartner, M. P., & Volkmann, C. (2022) · Nervenheilkunde · doi:10.1055/a-1761-3192 · Cited by 2
Ramming, H., Theuerkauf, L., Hoos, O., Lichter, K., & Kittel‐Schneider, S. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05849-2 · Cited by 2
Canuso, C. M., Bossie, C. A., Fu, D., Lane, R., Doherty, T., Lignugaris, A., Fagiolini, A. M., Llorca, P., McIntyre, R. S., Reif, A., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250250 · Cited by 2
Self-citationWilkinson, S. T., Prashad, S., Dalthorp, R., Harding, L., Kitay, B. M., Parikh, S. V., Dziura, J. D., Clayton, A. R., Fram, G., Lepoutre, V., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108273 · Cited by 2
Baune, B., Rosemann, K., Hefter, D., Tonkul, M., & Kavakbasi, E. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-07980-8 · Cited by 2
Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science
van Hoogdalem, M. W., Fu, D., Drevets, W. C., & Zannikos, P. (2026) · Clinical and Translational Science · doi:10.1111/cts.70527 · Cited by 2
Self-citationLiu, T.-H., Shen, H.-S., Wu, J., Huang, P., Shih, Y.-J., & Lai, C.-C. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04032-3 · Cited by 2
Krivosova, M., Marcatili, M., Guerrera, G., Cornaggia, R. D., Motta, F. L., Paolini, T., Gamba, B., Giampieri, E., Bertola, F., Benatti, B., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1783538 · Cited by 2
Guglielmo, R., Olivola, M., Inuggi, A., Cavanna, E., Briasco, E., da Silva, B. P., Escelsior, A., Giacomini, G., Martinotti, G., Dell’Osso, B. M., et al. (2026) · European Psychiatry · doi:10.1192/j.eurpsy.2026.12233 · Cited by 2
Mazzoni, F., Raffone, F., Ciechi, A. D., Girone, N., Macellaro, M., Martinotti, G., Dell’Osso, B. M., Martiadis, V., & Olivola, M. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117288 · Cited by 2
Bellanti, P. A., Lewis, J., Seifferth, B., & Adams, D. Z. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1867963 · Cited by 2
Role of the Pharmacist in Managing Treatment-Resistant Depression: A Focus on Ketamine
Liu, L. X. Y., Golts, M., & Fernandes, V. (2021) · Pharmacy · doi:10.3390/pharmacy9030118 · Cited by 2
Esketamine for treatment-resistant depression in adults
Gastaldon, C., Laurenzi, P. F., Schoretsanitis, G., Papola, D., Cristea, I. A., Naudet, F., Ostuzzi, G., & Barbui, C. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015071 · Cited by 2
Translational Neuropsychopharmacology for Major Depression: Targeting Neurotransmitter Systems
Kim, H., Kim, Y., & Jeon, H. J. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_15 · Cited by 2
Mungo, A., & Hein, M. (2022) · L Encéphale · doi:10.1016/j.encep.2021.12.002 · Cited by 2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.045 · Cited by 2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.017 · Cited by 2
Otto, M. E., Bergmann, K. R., de Kam, M. L., Recourt, K., Jacobs, G. E., & van Esdonk, M. J. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13018 · Cited by 2
Kheirabadi, G., & Golkar, S. (2023) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.5812/ijpbs-137879 · Cited by 2
Zhu, M., Lv, S., Zhu, F., & Zhang, Y. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001966 · Cited by 2
Zheng, F., Hu, Z., Chen, H., Cheng, J., Hou, Q., Zheng, J., Gong, X., Ji, J., Zayniddin, N., Abduahadi, S., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117538 · Cited by 2
Busz, A., Schmidt, E. (. J. )., van den Brink, R., Foeken, K., de Jong, M., Mertens, J. (. B. C. )., van Noorden, M. S., Olivier, E. (. J. F. L. )., Schruers, K. R. J., Schutters, S. I. J., et al. (2025) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2025.100905 · Cited by 2
Research trends in esketamine for depression over the past decade: a bibliometric analysis
Zhang, B., Liu, Y., Zheng, J., & Chen, J. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1621830 · Cited by 2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.024 · Cited by 2
Marcatili, M., Borgonovo, R., Cimminiello, N., Cornaggia, R. D., Casati, G., Pellicioli, C., Maggioni, L., Motta, F. L., Chiara, R., Ledda, L., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091524 · Cited by 2
Факторы риска суицидального поведения при биполярном аффективном расстройстве
Васильева, С. Н., Simutkin, G. G., Schastnyy, E. D., & Bokhan, N. A. (2022) · Суицидология · doi:10.32878/suiciderus.22-13-01(46)-118-127 · Cited by 2
Treatment-resistant psychotic depression
Koretski, J. A., & Rothschild, A. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00024-4 · Cited by 2
Recent advances and challenges in major depressive disorder
Kim, Y. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110403 · Cited by 2
Hack, L. M., Warthen, K., Zhang, X., Heifets, B. D., Suppes, T. M., van Roessel, P., Rodríguez, C. I., Knutson, B. D., & Williams, L. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.20.460992 · Cited by 2
Recent Advances in Psychopharmacology
Poznanski, A. J., & Akinyemi, E. (2022) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2022.03.009 · Cited by 2
Naudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Pabic, E. L., & Cristea, I. A. (2025) · medRxiv · doi:10.1101/2025.07.17.25331696 · Cited by 2
Plöderl, M., Cooper, R. E., Walker, T., Shah, V., Horowitz, M. A., Volkmann, C., & Moncrieff, J. (2025) · medRxiv · doi:10.1101/2025.08.19.25333796 · Cited by 2
Gowthami, B., Mehta, I., Baiju, S., Appani, A., Suvarna, T., Randhawa, K., Kakkad, A. M., Syed, A. B., Kumar, V., Ramteke, H. D., et al. (2025) · medRxiv · doi:10.1101/2025.09.22.25336317 · Cited by 2
Mystical Experience Induced by Esketamine Treatment: A Real-World Observational StudyPreprint
Mallevays, M., Fuet, L., Danon, M., Lodovico, L. D., Jaffré, C., Bouzeghoub, L., Mrad, S. M., Rousselet, A.-V., Allary, L., Müh, C., et al. (2026) · medRxiv · doi:10.64898/2026.03.31.26349757 · Cited by 2
Self-citationXie, J., Pu, C., & Sun, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1774549 · Cited by 1
Motamed, H., Moezi, M., Khilghi, A., & Fahimi, M. A. (2022) · Immunopathologia Persa · doi:10.34172/ipp.2022.30334 · Cited by 1
QUETAMINA COMO MODALIDADE TERAPÊUTICA PARA ENXAQUECA E CEFALÉIA TENSIONAL: UMA REVISÃO DE LITERATURA
de Menezes, J. B. T., de Souza, S. L., Lira, M. Z. R. D. F., Oliveira, M. D. S. L., de Queiroz, A. S. S. B., de Queiroz, A. S. S. B., Filho, M. L. D. P. D. O., Leite, M. B., de Oliveira, I. C., Martins, M. A. R., et al. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i10.12107 · Cited by 1
Ketamine - precursor of a new generation antidepressant drugs
Zawilska, J. B., & Zwierzyńska, E. (2024) · Farmacja Polska · doi:10.32383/farmpol/186596 · Cited by 1
Esketamine-Induced Dissociation: A Case Report
Scarcella, J., MacDaniels, J. S., Coffin, L., & Schwartz, T. L. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2424283 · Cited by 1
Saran, B., Bhagat, T. S., & Bhagat, R. (2024) · Santosh University Journal of Health Sciences · doi:10.4103/sujhs.sujhs_60_24 · Cited by 1
Dutra, R. N., Nascimento, M. V. F., Gontijo, J. P. S., LISBOA, K. S., Viana, G. F., Coelho, N. C., Dutra, S. M., & Alves, B. D. M. L. (2025) · STUDIES IN HEALTH SCIENCES · doi:10.54022/shsv6n1-037 · Cited by 1
Beyond surgery: Repurposing anesthetics for treatment of central nervous system disorders
Mielko, J., Pakulska, J., Oszczyk, A., Lustyk, K., Pytka, K., & Sałaciak, K. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111386 · Cited by 1
Samalin, L., Boudieu, L., & Llorca, P. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_14 · Cited by 1
Viana, V. G., Lima, D. D. J., Rodrigues, D. R., Filho, J. G. S., Bandeira, S. R. D. J., Barbieri, C. A., Alves, A. D. S., da Silva, L. L. D. A. R., SILVA, L. C. A. D. M. P. S. D., Lourenço, J. V. E. F., et al. (2025) · LUMEN ET VIRTUS · doi:10.56238/levv16n53-149 · Cited by 1
Wang, R., Jin, Y., Zou, B., & Ding, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1699304 · Cited by 1
Sarlon, J., Thomi, D., Brühl, A. B., Liwinski, T., & Lang, U. E. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121208 · Cited by 1
Liu, J.-M., Zhang, Y., Guo, F., Li, B.-W., Chen, H., Mo, Y., Kong, J., Tan, X., Wu, W., & Cao, X. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03874-1 · Cited by 1
Advances in antidepressant pharmacotherapy: phase 3 evidence and clinical perspectives
Cuomo, A., Pinzi, M., & Fagiolini, A. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2634195 · Cited by 1
Almadani, A. H., Alghamdi, A. H., Almazyad, G. M., Alfawaz, S. I., Ghaith, M. A.-A., Alshehri, A. A., Aljaffer, M. A., & Alghamdi, S. A. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1726411 · Cited by 1
Otto, M. E., Jacobs, G. E., van Mechelen, J., Borghans, L. G. J. M., van Hasselt, J. G. C., & Aulin, L. B. S. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70503 · Cited by 1
Li, Y., Chan, V. K. Y., Jit, M., Cheng, F. W. T., Yiu, H. H. E., Bishai, D. M., Craig, D., Chan, E. W., Chan, S. S. M., & Li, X. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1005047 · Cited by 1
Cuomo, A., McIntyre, R. S., Koukouna, D., Pinzi, M., Pardossi, S., Firenzuoli, B., Barillà, G., Carmellini, P., Alamia, A., & Fagiolini, A. M. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261437597 · Cited by 1
Qu, Y., Li, S., Tian, L., Tian, X., & Wu, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1792570 · Cited by 1
Martiadis, V., Raffone, F., Atripaldi, D., Pessina, E., Cattaneo, C. I., Testa, S., Iaccarino, C., d’Andrea, G., Cavallotto, C., Olivola, M., et al. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-026-02361-4 · Cited by 1
Llorca, P., Sauvaget, A., Olié, É., Mékaoui, L., Samalin, L., Rothärmel, M., Boitez, A.-L., Dupin, J., Wicart, C., Gaudre-Wattinne, E., et al. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261463652 · Cited by 1
Pompili, M., Sarubbi, S., Biase, G. D., Roberto, P., Fascetti, W., Trocchia, M. A., Erbuto, D., & Berardelli, I. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.09.005 · Cited by 1
Feifel, D., Seynaeve, M., Cubała, W. J., Dunbar, F., Gründer, G., Herrero, R. M. D., Hindocha, C., Liknaitzky, P., Mcguigan, S., Mehta, S., et al. (2026) · JAMA · doi:10.1001/jama.2026.18380 · Cited by 1
Intranasal esketamine in treatment-resistant depression: a profile of its use
Scott, L. J. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00675-z · Cited by 1
Recent Advances in Ketamine Research: An Update
Raj, T. Y., & Ren, Q. (2020) · Open Journal of Anesthesiology · doi:10.4236/ojanes.2020.103008 · Cited by 1
Esketamine: the first glutamatergic drug for the management of treatment- resistant depression
Musazzi, L. (2020) · doi:10.36118/pharmadvances.03.2020.02 · Cited by 1
Spravato oder die Frage: „Wie viel darf ein Antidepressivum kosten?“
Spießl, H. (2021) · Psychiatrische Praxis · doi:10.1055/a-1500-9805 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.083 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.018 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.032 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.086 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.046 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.055 · Cited by 1
Metadata
- Authors
- Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., Ravindran, A., Gaillard, R., Ameele, H. V. D., Preskorn, S., Manji, H., Hough, D., Drevets, W. C., & Singh, J. B.
- Affiliations
- Janssen Research and Development, Department of Neuroscience, Titusville, New Jersey
- The University of Texas Southwestern Medical Center (US)
- Janssen Research and Development, Clinical Biostatistics, Titusville, New Jersey
- University of Ottawa (CA)
- Clinical Trials Network and Institute, Massachusetts General Hospital, Boston, Massachusetts
- Medical Research Network (US)
- University of Toronto (CA)
- Centre Hospitalier Sainte Anne, Service Hospitalo-Universitaire, Paris, France
- AZ Sint-Jan (BE)
- University of Kansas (US)
- Janssen Research and Development, Department of Neuroscience, San Diego, California
- Corresponding author
- Fedgchin, Maggie
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-10
- Volume
- 22
- Issue
- 10
- Pages
- 616-630
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC6822141
- OpenAlex
- W2961020354
- Semantic Scholar
- 3739b211f156e1c4836c25e44222f6497502cdd7
- Cited by
- 606
- References
- 32
- Citations by year
- 2026: 49 · 2025: 73 · 2024: 58 · 2023: 59 · 2022: 72 · 2021: 62 · 2020: 222 · 2019: 10
- FWCI
- 56.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- esketamine, nasal spray, treatment-resistant depression, antidepressant combination therapy, rapid-acting antidepressants, antidepressant non-response, depression remission, adverse events, dissociation, nausea
- MeSH terms
- Duloxetine Hydrochloride, Venlafaxine Hydrochloride, Administration, Intranasal, Administration, Oral, Adolescent, Adult, Antidepressive Agents, Delayed-Action Preparations, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Ketamine, Male, Middle Aged, Citalopram, Treatment Outcome, Sertraline, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.